ArteryFlow

What ArteryFlow does

ArteryFlow (脉流科技) is a Hangzhou-based medical technology company founded in 2020 that develops AI-powered diagnostic systems for cardiovascular and cerebrovascular diseases. The company applies deep learning algorithms, computational fluid dynamics (CFD) analysis, and medical imaging processing to deliver non-invasive functional assessments for coronary artery disease, intracranial aneurysms, stroke, and cardiac conditions. Its product portfolio is organized into two solution lines: cerebrovascular intelligent diagnosis (AneuFlow, AneuGuide, AneuShape, AneuPlan, AccuASPECTS, AccuCTP, AccuFFicas/AccuICAS) and cardiovascular intelligent diagnosis (AccuFFRct, AccuFFRangio, AccuFFRivus, AccuFFRoct, AccuLV, AccuIMR). The company has filed over 100 patents and the founding team has published hundreds of academic papers in cardiovascular and cerebrovascular research.

The company's technical differentiators include the AccuFFRangio system's wire-free coronary angiography-based FFR technology, which eliminates the need for guidewire-based pressure measurements traditionally required for functional assessment of myocardial ischemia, and the AneuFlow platform for intracranial aneurysm rupture risk prediction. The AccuICAS intracranial stenosis assessment product received U.S. FDA 510(k) clearance in February 2023, while AccuLV received Chinese domestic medical device registration in June 2024, marking the company's expansion into cardiac functional assessment. Products integrate deep learning-based image analysis with hemodynamic computation across multiple imaging modalities including CTA, DSA, MRA, IVUS, and OCT.

ArteryFlow operates a sales-led, business-to-hospital go-to-market model with direct sales to medical institutions in China and selective international expansion through the U.S. market via FDA-cleared products. Revenue is generated through one-time licensing of its diagnostic software products to hospitals, with over 100 hospitals engaged in deep clinical collaboration that supports both product development and commercial deployment. The company partners with the Gates Vascular Institute (GVI) in Buffalo, USA, for cardiovascular intervention research and development, and 70% of its staff work in medical clinical and research functions.

Name

ArteryFlow

Legal name

杭州脉流科技有限公司

Website

https://arteryflow.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

ArteryFlow (脉流科技) develops AI-powered diagnostic systems for cardiovascular and cerebrovascular diseases, selling non-invasive imaging and hemodynamic analysis software to hospitals in China and selectively in the U.S.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Software Publishers (513210)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industry

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

Keywords

• Cardiovascular diagnostic software
• Cerebrovascular disease imaging
• AI medical imaging solutions
• Non-invasive FFR analysis
• Computational fluid dynamics healthcare

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel

Revenue model

1. Medical Device Sales: Sale of diagnostic software products for cardiovascular and cerebrovascular disease assessment. Products include AccuFFR series, AneuFlow, AccuLV, and other AI-powered diagnostic systems sold to hospitals and medical institutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ArteryFlow develops and sells AI-powered diagnostic software for cardiovascular and cerebrovascular diseases. Its portfolio includes the AccuFFR series for non-invasive coronary functional assessment, the AneuFlow/AneuGuide system for intracranial aneurysm diagnosis and surgical planning, AccuCTP for stroke perfusion analysis, and AccuLV for cardiac functional assessment. These software products are sold to hospitals and clinical departments to enable non-invasive, image-based disease diagnosis and treatment planning.

Product overview

ArteryFlow (脉流科技) is a medical technology company providing intelligent diagnosis and treatment solutions for cardiovascular and cerebrovascular diseases. The company offers a comprehensive portfolio organized into two main solution areas: Cerebrovascular Intelligent Diagnosis Solutions (including AneuFlow, AneuGuide, AneuShape, AneuPlan, AccuASPECTS, AccuCTP, AccuFFicas) and Cardiovascular Intelligent Diagnosis Solutions (AccuFFRct, AccuFFRangio, AccuFFRivus, AccuFFRoct, AccuLV, AccuIMR). The company has developed three major coronary functional assessment systems (AccuFFR series) and provides complete cardiovascular and cerebrovascular disease solutions. Products utilize deep learning algorithms, hemodynamic analysis algorithms, and medical imaging technologies. The AccuFFRangio specifically pioneered wire-free FFR testing, while the AccuFFR series and AneuFlow products cover screening, diagnosis, and treatment planning across the care continuum.

Differentiator

Problem solved

Functional benefit

Brands

• AccuFFR: Coronary functional assessment product line including AccuFFRct (CTA-based non-invasive FFR), AccuFFRangio (angiography-based FFR), AccuFFRivus (IVUS-based FFR), and AccuFFRoct (OCT-based FFR)
• AneuFlow
• AneuGuide
• AneuShape
• AccuCTP
• AccuICAS
• AccuLV
• AccuIMR

Products and services

• AneuFlow AI-assisted intracranial aneurysm diagnosis system based on DSA, CTA, and MRA imaging that determines aneurysm rupture risk for precise screening and diagnosis. Sold to neurosurgery and neurointerventional radiology departments.
• AneuGuide Real-time intracranial aneurysm surgical planning system providing precise flow diverter stent selection reference and microcatheter shaping guidance. For neurosurgery and interventional radiology departments.
• AneuShape Microcatheter shaping product used in intracranial aneurysm interventional procedures.
• AneuPlan Surgical planning system for intracranial aneurysm procedures, complementing AneuGuide for pre-operative planning.
• AccuASPECTS Automated ASPECTS (Alberta Stroke Program Early CT Score) scoring software for rapid, consistent stroke diagnosis from CT imaging.
• AccuCTP Automated intracranial CT perfusion imaging analysis software that rapidly and precisely quantifies cerebral infarction extent to support timely stroke treatment.
• AccuFFicas Intracranial artery stenosis one-stop evaluation software based on DSA and CTA imaging that determines stenosis severity for treating atherosclerosis and preventing stroke.
• AccuFFRct Non-invasive FFR (Fractional Flow Reserve) software based on coronary CTA imaging for rapid and precise quantitative analysis of myocardial ischemia.
• AccuFFRangio Wire-free FFR software based on coronary angiography that delivers functional assessment of myocardial ischemia without invasive guidewire pressure measurement.
• AccuFFRivus FFR software based on IVUS (Intravascular Ultrasound) for comprehensive coronary assessment.
• AccuFFRoct FFR software based on OCT (Optical Coherence Tomography) for detailed coronary visualization and functional assessment.
• AccuLV Non-invasive cardiac functional assessment software using image processing and deep learning technologies to assist clinicians with cardiac functional evaluation. NMPA-approved in China in 2024.
• AccuIMR Coronary microcirculation resistance evaluation software that assesses microvascular-level myocardial ischemia and complements macro-level FFR diagnostics.
• AccuICAS Intracranial arterial stenosis functional assessment software that received US FDA 510(k) clearance, enabling one-stop evaluation of intracranial stenosis for stroke prevention.

Quantifiable outcome

• 100min hemodynamic analysis time for AccuFFRangio
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

One partnership is on record.

• Gates Vascular Institute (GVI), Buffalo, USAcoreStrategic or Co-development PartnerDeep cooperation with world-class interventional center in the United States. The company collaborates with GVI for research and development in cardiovascular interventions, leveraging international clinical expertise.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Viz.ai: Viz.ai is an AI platform specializing in stroke and cerebrovascular disease detection and care coordination. It overlaps with ArteryFlow's AccuCTP and AccuASPECTS for stroke triage and shares the same hospital sales motion into neurology and neurointerventional departments.
• HeartFlow: HeartFlow is the global leader in non-invasive CT-FFR for coronary artery disease. Its HeartFlow Analysis directly competes with ArteryFlow's AccuFFRct in the CT-based non-invasive FFR category, serving the same cardiology customer base with a similar AI/CFD-driven diagnostic value proposition and pursuing the same FDA-cleared, reimbursement-supported commercialization model.
• RapidAI: RapidAI provides AI-driven imaging analysis for stroke and cerebrovascular disease, including CT perfusion, ASPECTS scoring, and aneurysm analysis. Its portfolio directly overlaps ArteryFlow's AneuFlow, AccuCTP, AccuASPECTS, and AccuFFicas products, serving the same neurointerventional hospital customers with comparable AI diagnostic workflows.
• Circle Cardiovascular Imaging: Circle CVI provides AI-based cardiac MR and CT analysis software including strain analysis and functional assessment. Its cardiac function evaluation capabilities overlap with ArteryFlow's AccuLV product, serving the same cardiology imaging customer base.

Broad incumbents

• GE HealthCare: GE HealthCare provides CT, MR, and angiography imaging systems used in cardiovascular and neurovascular diagnosis. Its Edison AI platform and partner ecosystem overlap with ArteryFlow's AI diagnostic value proposition and represent an OEM bundling threat for standalone AI vendors.
• Siemens Healthineers: Siemens Healthineers is a global medical imaging and diagnostics incumbent with deep cardiology and neurology imaging portfolios (CT, MR, angiography). Its syngo.via and AI-Rad Companion platforms increasingly embed diagnostic AI that competes with ArteryFlow's offerings, and its installed-base relationships with hospitals create indirect competitive pressure even when ArteryFlow sells standalone.
• Philips: Philips is a major cardiovascular and neurovascular imaging incumbent through its Image Guided Therapy and Diagnostic Imaging businesses. Its IntelliSpace AI and stratagem analytics platforms serve the same cardiology and neurointerventional hospital customers and increasingly embed AI diagnostic workflows.
• Canon Medical Systems: Canon Medical provides CT, MR, and angiography systems with AI-enabled cardiac and neurological analysis (AiCE, Olea Medical integration). Its installed base of imaging equipment creates the same hospital-channel competitive dynamic that ArteryFlow must navigate in both cardiology and neurointervention.

Emerging players

• Olea Medical: Olea Medical specializes in MR and CT perfusion imaging analysis for stroke and oncology, with overlap to ArteryFlow's AccuCTP. Now part of Canon Medical, it represents a competitive neurovascular perfusion analysis workflow targeting the same neurointerventional departments.

Regional players

• Shukun Technology: Shukun Technology is a Chinese AI medical imaging company focused on cardiovascular and cerebrovascular disease diagnosis using deep learning. It is a direct Chinese-market competitor to ArteryFlow, targeting the same cardiology and neurology hospital customers with comparable AI imaging diagnostic products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/arteryflow-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ArteryFlow